Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention
Background Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been...
Gespeichert in:
Veröffentlicht in: | International urology and nephrology 2015-03, Vol.47 (3), p.521-525 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 525 |
---|---|
container_issue | 3 |
container_start_page | 521 |
container_title | International urology and nephrology |
container_volume | 47 |
creator | Firouzi, Ata Maadani, Mohsen Kiani, Reza Shakerian, Farshad Sanati, Hamid Reza Zahedmehr, Ali Nabavi, Seyedabbas Heidarali, Mona |
description | Background
Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention.
Method and design
This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment (
n
= 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure (
n
= 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25 % or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present.
Results
The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6 %) patients in the control group and nine (14.5 %) patients in the study group; there was a significant reduction in CI-AKI in the study group (
P
= 0.01). Additionally, there was no mortality or a need for hemodialysis in either group.
Conclusion
In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention. |
doi_str_mv | 10.1007/s11255-014-0890-z |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1659770661</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3605313261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-faecaff5da804ea36e88fc40498178e1feec2edc9a80686b4b7293fd37602f693</originalsourceid><addsrcrecordid>eNp1kUFrFTEUhYMo9rX6A9xIwI2b6E1mJsm4k6K1UHCj65CXuemb8iYZk4zS7v3fZpiniOAqkPudc8_lEPKCwxsOoN5mzkXXMeAtA90De3hEdrxTDROdbh-THTTAGZeiOSPnOd8BQK8BnpIz0bWq473ckZ_XoST7HUNcMp3sbcA8LhPNy9Hbgu9owB90wnKIAx0DnRNWtIwx0Oipi6s2FzaGYXE4VHg-pDjbcrjf6HGy6Z7OmNxSbMB1h4sphvV3DAXTye0ZeeLtMePz03tBvn788OXyE7v5fHV9-f6GubYVhXmLznrfDVZDi7aRqLV3LbS95koj94hO4OD6Opda7tu9En3jh0ZJEF72zQV5vfnOKX5bMBczjdnh8biFM1x2vVIgJa_oq3_Qu7ikUNOtlG5qAqEqxTfKpZhzQm9ORxsOZu3IbB2Z2pFZOzIPVfPy5LzsJxz-KH6XUgGxAbmOwi2mv1b_1_UXgo6hOw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1658380427</pqid></control><display><type>article</type><title>Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Firouzi, Ata ; Maadani, Mohsen ; Kiani, Reza ; Shakerian, Farshad ; Sanati, Hamid Reza ; Zahedmehr, Ali ; Nabavi, Seyedabbas ; Heidarali, Mona</creator><creatorcontrib>Firouzi, Ata ; Maadani, Mohsen ; Kiani, Reza ; Shakerian, Farshad ; Sanati, Hamid Reza ; Zahedmehr, Ali ; Nabavi, Seyedabbas ; Heidarali, Mona</creatorcontrib><description>Background
Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention.
Method and design
This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment (
n
= 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure (
n
= 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25 % or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present.
Results
The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6 %) patients in the control group and nine (14.5 %) patients in the study group; there was a significant reduction in CI-AKI in the study group (
P
= 0.01). Additionally, there was no mortality or a need for hemodialysis in either group.
Conclusion
In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention.</description><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1007/s11255-014-0890-z</identifier><identifier>PMID: 25475196</identifier><identifier>CODEN: IURNAE</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Acute Kidney Injury - blood ; Acute Kidney Injury - chemically induced ; Acute Kidney Injury - prevention & control ; Administration, Intravenous ; Aged ; Calcium Channel Blockers - administration & dosage ; Contrast Media - adverse effects ; Creatinine - blood ; Female ; Humans ; Magnesium Sulfate - administration & dosage ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Nephrology ; Nephrology - Original Paper ; Percutaneous Coronary Intervention - adverse effects ; Prospective Studies ; Urology</subject><ispartof>International urology and nephrology, 2015-03, Vol.47 (3), p.521-525</ispartof><rights>Springer Science+Business Media Dordrecht 2014</rights><rights>Springer Science+Business Media Dordrecht 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-faecaff5da804ea36e88fc40498178e1feec2edc9a80686b4b7293fd37602f693</citedby><cites>FETCH-LOGICAL-c442t-faecaff5da804ea36e88fc40498178e1feec2edc9a80686b4b7293fd37602f693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11255-014-0890-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11255-014-0890-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27906,27907,41470,42539,51301</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25475196$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Firouzi, Ata</creatorcontrib><creatorcontrib>Maadani, Mohsen</creatorcontrib><creatorcontrib>Kiani, Reza</creatorcontrib><creatorcontrib>Shakerian, Farshad</creatorcontrib><creatorcontrib>Sanati, Hamid Reza</creatorcontrib><creatorcontrib>Zahedmehr, Ali</creatorcontrib><creatorcontrib>Nabavi, Seyedabbas</creatorcontrib><creatorcontrib>Heidarali, Mona</creatorcontrib><title>Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><addtitle>Int Urol Nephrol</addtitle><description>Background
Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention.
Method and design
This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment (
n
= 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure (
n
= 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25 % or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present.
Results
The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6 %) patients in the control group and nine (14.5 %) patients in the study group; there was a significant reduction in CI-AKI in the study group (
P
= 0.01). Additionally, there was no mortality or a need for hemodialysis in either group.
Conclusion
In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention.</description><subject>Acute Kidney Injury - blood</subject><subject>Acute Kidney Injury - chemically induced</subject><subject>Acute Kidney Injury - prevention & control</subject><subject>Administration, Intravenous</subject><subject>Aged</subject><subject>Calcium Channel Blockers - administration & dosage</subject><subject>Contrast Media - adverse effects</subject><subject>Creatinine - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Magnesium Sulfate - administration & dosage</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Nephrology - Original Paper</subject><subject>Percutaneous Coronary Intervention - adverse effects</subject><subject>Prospective Studies</subject><subject>Urology</subject><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kUFrFTEUhYMo9rX6A9xIwI2b6E1mJsm4k6K1UHCj65CXuemb8iYZk4zS7v3fZpiniOAqkPudc8_lEPKCwxsOoN5mzkXXMeAtA90De3hEdrxTDROdbh-THTTAGZeiOSPnOd8BQK8BnpIz0bWq473ckZ_XoST7HUNcMp3sbcA8LhPNy9Hbgu9owB90wnKIAx0DnRNWtIwx0Oipi6s2FzaGYXE4VHg-pDjbcrjf6HGy6Z7OmNxSbMB1h4sphvV3DAXTye0ZeeLtMePz03tBvn788OXyE7v5fHV9-f6GubYVhXmLznrfDVZDi7aRqLV3LbS95koj94hO4OD6Opda7tu9En3jh0ZJEF72zQV5vfnOKX5bMBczjdnh8biFM1x2vVIgJa_oq3_Qu7ikUNOtlG5qAqEqxTfKpZhzQm9ORxsOZu3IbB2Z2pFZOzIPVfPy5LzsJxz-KH6XUgGxAbmOwi2mv1b_1_UXgo6hOw</recordid><startdate>20150301</startdate><enddate>20150301</enddate><creator>Firouzi, Ata</creator><creator>Maadani, Mohsen</creator><creator>Kiani, Reza</creator><creator>Shakerian, Farshad</creator><creator>Sanati, Hamid Reza</creator><creator>Zahedmehr, Ali</creator><creator>Nabavi, Seyedabbas</creator><creator>Heidarali, Mona</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20150301</creationdate><title>Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention</title><author>Firouzi, Ata ; Maadani, Mohsen ; Kiani, Reza ; Shakerian, Farshad ; Sanati, Hamid Reza ; Zahedmehr, Ali ; Nabavi, Seyedabbas ; Heidarali, Mona</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-faecaff5da804ea36e88fc40498178e1feec2edc9a80686b4b7293fd37602f693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acute Kidney Injury - blood</topic><topic>Acute Kidney Injury - chemically induced</topic><topic>Acute Kidney Injury - prevention & control</topic><topic>Administration, Intravenous</topic><topic>Aged</topic><topic>Calcium Channel Blockers - administration & dosage</topic><topic>Contrast Media - adverse effects</topic><topic>Creatinine - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Magnesium Sulfate - administration & dosage</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Nephrology - Original Paper</topic><topic>Percutaneous Coronary Intervention - adverse effects</topic><topic>Prospective Studies</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Firouzi, Ata</creatorcontrib><creatorcontrib>Maadani, Mohsen</creatorcontrib><creatorcontrib>Kiani, Reza</creatorcontrib><creatorcontrib>Shakerian, Farshad</creatorcontrib><creatorcontrib>Sanati, Hamid Reza</creatorcontrib><creatorcontrib>Zahedmehr, Ali</creatorcontrib><creatorcontrib>Nabavi, Seyedabbas</creatorcontrib><creatorcontrib>Heidarali, Mona</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Firouzi, Ata</au><au>Maadani, Mohsen</au><au>Kiani, Reza</au><au>Shakerian, Farshad</au><au>Sanati, Hamid Reza</au><au>Zahedmehr, Ali</au><au>Nabavi, Seyedabbas</au><au>Heidarali, Mona</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention</atitle><jtitle>International urology and nephrology</jtitle><stitle>Int Urol Nephrol</stitle><addtitle>Int Urol Nephrol</addtitle><date>2015-03-01</date><risdate>2015</risdate><volume>47</volume><issue>3</issue><spage>521</spage><epage>525</epage><pages>521-525</pages><issn>0301-1623</issn><eissn>1573-2584</eissn><coden>IURNAE</coden><abstract>Background
Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention.
Method and design
This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment (
n
= 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure (
n
= 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25 % or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present.
Results
The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6 %) patients in the control group and nine (14.5 %) patients in the study group; there was a significant reduction in CI-AKI in the study group (
P
= 0.01). Additionally, there was no mortality or a need for hemodialysis in either group.
Conclusion
In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>25475196</pmid><doi>10.1007/s11255-014-0890-z</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0301-1623 |
ispartof | International urology and nephrology, 2015-03, Vol.47 (3), p.521-525 |
issn | 0301-1623 1573-2584 |
language | eng |
recordid | cdi_proquest_miscellaneous_1659770661 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Acute Kidney Injury - blood Acute Kidney Injury - chemically induced Acute Kidney Injury - prevention & control Administration, Intravenous Aged Calcium Channel Blockers - administration & dosage Contrast Media - adverse effects Creatinine - blood Female Humans Magnesium Sulfate - administration & dosage Male Medicine Medicine & Public Health Middle Aged Nephrology Nephrology - Original Paper Percutaneous Coronary Intervention - adverse effects Prospective Studies Urology |
title | Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T11%3A27%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravenous%20magnesium%20sulfate:%20new%20method%20in%20prevention%20of%20contrast-induced%20nephropathy%20in%20primary%20percutaneous%20coronary%20intervention&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Firouzi,%20Ata&rft.date=2015-03-01&rft.volume=47&rft.issue=3&rft.spage=521&rft.epage=525&rft.pages=521-525&rft.issn=0301-1623&rft.eissn=1573-2584&rft.coden=IURNAE&rft_id=info:doi/10.1007/s11255-014-0890-z&rft_dat=%3Cproquest_cross%3E3605313261%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1658380427&rft_id=info:pmid/25475196&rfr_iscdi=true |